These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 11728356)

  • 1. A risk stratification scheme for selection of a glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention based on clinical and angiographic criteria.
    Kini AS; Reich D; Mitre CA; Sharma SK
    Am J Cardiol; 2001 Dec; 88(11):1287-90. PubMed ID: 11728356
    [No Abstract]   [Full Text] [Related]  

  • 2. A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.
    Gurm HS; Tamhane U; Meier P; Grossman PM; Chetcuti S; Bates ER
    Circ Cardiovasc Interv; 2009 Jun; 2(3):230-6. PubMed ID: 20031720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of tirofiban, eptifibatide, and abciximab in minimizing myocardial necrosis during percutaneous coronary intervention (TEAM pilot study).
    Kini AS; Richard M; Suleman J; Perez N; Lee P; Fisher EA; Kamran M; Marmur JD; Sharma SK
    Am J Cardiol; 2002 Sep; 90(5):526-9. PubMed ID: 12208416
    [No Abstract]   [Full Text] [Related]  

  • 4. Monitoring platelet function in glycoprotein IIB/IIIA inhibitor therapy.
    Wu KK; Willerson JT
    Circulation; 2001 May; 103(21):2528-30. PubMed ID: 11382717
    [No Abstract]   [Full Text] [Related]  

  • 5. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Bhatt DL; Topol EJ
    JAMA; 2000 Sep; 284(12):1549-58. PubMed ID: 11000650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
    Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA
    Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease.
    Lincoff AM; Califf RM; Topol EJ
    J Am Coll Cardiol; 2000 Apr; 35(5):1103-15. PubMed ID: 10758948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutics of platelet glycoprotein IIb/IIIa receptor antagonism.
    Gowda RM; Khan IA; Vasavada BC; Sacchi TJ
    Am J Ther; 2004; 11(4):302-7. PubMed ID: 15266223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention.
    Brown DL; Fann CS; Chang CJ
    Am J Cardiol; 2001 Mar; 87(5):537-41. PubMed ID: 11230835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention.
    Kereiakes DJ; Broderick TM; Roth EM; Whang D; Shimshak T; Runyon JP; Hattemer C; Schneider J; Lacock P; Mueller M; Abbottsmith CW
    Am J Cardiol; 1999 Aug; 84(4):391-5. PubMed ID: 10468074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic issues in glycoprotein IIb/IIIa receptor therapy.
    Hillegass WB; Newman AR; Raco DL
    Am Heart J; 1999 Jul; 138(1 Pt 2):S24-32. PubMed ID: 10385788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
    N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergency coronary artery bypass surgery in the era of glycoprotein IIb/IIIa receptor antagonist use.
    Pang JT; Fort S; Della Siega A; Cohen EA
    J Card Surg; 2002; 17(5):425-31. PubMed ID: 12630543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycoprotein IIb/IIIa inhibitors in patients with renal insufficiency undergoing percutaneous coronary intervention.
    Anderson JR; Riding D
    Cardiol Rev; 2008; 16(4):213-8. PubMed ID: 18562812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trials of platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary revascularization.
    Lincoff AM
    Am J Cardiol; 1998 Oct; 82(8B):36P-42P. PubMed ID: 9809890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention.
    Suleiman M; Gruberg L; Hammerman H; Aronson D; Halabi M; Goldberg A; Grenadier E; Boulus M; Markiewicz W; Beyar R
    J Invasive Cardiol; 2003 Jun; 15(6):319-23. PubMed ID: 12777670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study.
    Steinhubl SR; Talley JD; Braden GA; Tcheng JE; Casterella PJ; Moliterno DJ; Navetta FI; Berger PB; Popma JJ; Dangas G; Gallo R; Sane DC; Saucedo JF; Jia G; Lincoff AM; Theroux P; Holmes DR; Teirstein PS; Kereiakes DJ
    Circulation; 2001 May; 103(21):2572-8. PubMed ID: 11382726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycoprotein IIb/IIIa receptor inhibition in interventional cardiology.
    Gibson CM; Moynihan JL; Al-Mousa EN; Campsey M; Gandhi R; Murphy S; Mattson S; Ryan KA; Mesley R; Swanson J; Arshad MN; Marble SJ
    J Thromb Thrombolysis; 1999 Jun; 7(3):287-302. PubMed ID: 10375390
    [No Abstract]   [Full Text] [Related]  

  • 19. [Comparison of 2 platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization].
    Rossi ML; Merlini PA
    Ital Heart J Suppl; 2001 Oct; 2(10):1130-2. PubMed ID: 11723620
    [No Abstract]   [Full Text] [Related]  

  • 20. [Therapy of acute coronary syndrome with glycoprotein IIb/IIIa antagonists].
    Araujo R; Agustí A
    Med Clin (Barc); 2000 Oct; 115(11):435-7. PubMed ID: 11093849
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.